247 related articles for article (PubMed ID: 34043691)
1. Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study.
Yen HH; Su PY; Huang SP; Wu L; Hsu TC; Zeng YH; Chen YY
PLoS One; 2021; 16(5):e0252286. PubMed ID: 34043691
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history.
Magrì S; Paduano D; Chicco F; Cingolani A; Farris C; Delogu G; Tumbarello F; Lai M; Melis A; Casula L; Fantini MC; Usai P
World J Gastroenterol; 2019 Oct; 25(37):5676-5686. PubMed ID: 31602167
[TBL] [Abstract][Full Text] [Related]
3. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.
Saroli Palumbo C; Restellini S; Chao CY; Aruljothy A; Lemieux C; Wild G; Afif W; Lakatos PL; Bitton A; Cocciolillo S; Ghali P; Bessissow T; Sebastiani G
Inflamm Bowel Dis; 2019 Jan; 25(1):124-133. PubMed ID: 29889226
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
[TBL] [Abstract][Full Text] [Related]
5. Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease.
Shalimar ; Kumar R; Rout G; Kumar R; Yadav R; Das P; Aggarwal S; Gunjan D; Saraya A; Nayak B
Indian J Gastroenterol; 2020 Feb; 39(1):32-41. PubMed ID: 32185692
[TBL] [Abstract][Full Text] [Related]
6. Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study.
Abenavoli L; Spagnuolo R; Scarlata GGM; Scarpellini E; Boccuto L; Luzza F
Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38003983
[No Abstract] [Full Text] [Related]
7. Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China.
Yu XY; Song XX; Tong YL; Wu LY; Song ZY
Medicine (Baltimore); 2020 Nov; 99(48):e23360. PubMed ID: 33235107
[TBL] [Abstract][Full Text] [Related]
8. Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease.
Hyun HK; Lee HW; Park J; Park SJ; Park JJ; Kim TI; Lee JS; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU; Cheon JH
Gut Liver; 2024 Mar; 18(2):294-304. PubMed ID: 37203442
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare.
Ritaccio G; Stoleru G; Abutaleb A; Cross RK; Shetty K; Sakiani S; Wong U
Dig Dis Sci; 2021 Sep; 66(9):3186-3191. PubMed ID: 32894439
[TBL] [Abstract][Full Text] [Related]
10. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
Zamani M; Alizadeh-Tabari S; Singh S; Loomba R
Aliment Pharmacol Ther; 2022 Apr; 55(8):894-907. PubMed ID: 35274325
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
[TBL] [Abstract][Full Text] [Related]
13. The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database.
Alkhouri N; Almomani A; Le P; Payne JY; Asaad I; Sakkal C; Vos M; Noureddin M; Kumar P
BMC Gastroenterol; 2022 Jul; 22(1):366. PubMed ID: 35907827
[TBL] [Abstract][Full Text] [Related]
14. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients.
Mansour A; Mohajeri-Tehrani MR; Samadi M; Gerami H; Qorbani M; Bellissimo N; Poustchi H; Hekmatdoost A
Acta Diabetol; 2019 Nov; 56(11):1199-1207. PubMed ID: 31197470
[TBL] [Abstract][Full Text] [Related]
16. Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel Disease.
Navarro P; Gutiérrez-Ramírez L; Tejera-Muñoz A; Arias Á; Lucendo AJ
Nutrients; 2023 Oct; 15(21):. PubMed ID: 37960160
[TBL] [Abstract][Full Text] [Related]
17. Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up.
van Lingen E; Tushuizen ME; Steenhuis MEJ; van Deynen T; Martens J; Morales DD; van der Meulen-de Jong AE; Molendijk I; van der Marel S; Maljaars PWJ
Int J Colorectal Dis; 2022 Feb; 37(2):349-356. PubMed ID: 34791524
[TBL] [Abstract][Full Text] [Related]
18. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.
Shen F; Zheng RD; Mi YQ; Wang XY; Pan Q; Chen GY; Cao HX; Chen ML; Xu L; Chen JN; Cao Y; Zhang RN; Xu LM; Fan JG
World J Gastroenterol; 2014 Apr; 20(16):4702-11. PubMed ID: 24782622
[TBL] [Abstract][Full Text] [Related]
19. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
Sourianarayanane A; Garg G; Smith TH; Butt MI; McCullough AJ; Shen B
J Crohns Colitis; 2013 Sep; 7(8):e279-85. PubMed ID: 23158500
[TBL] [Abstract][Full Text] [Related]
20. Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients.
Carr RM; Patel A; Bownik H; Oranu A; Kerner C; Praestgaard A; Forde KA; Reddy KR; Lichtenstein GR
Dig Dis Sci; 2017 May; 62(5):1354-1361. PubMed ID: 28265826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
